Interní Med. 2008; 10(2): 50-53

The role of thiazolidindiones in the treatment of type 2 diabetes

prof. MUDr. Jaroslav Rybka DrSc1,2
1 Diabetologické centrum Baťovy nemocnice Zlín
2 Interní klinika, Krajská nemocnice T. Bati a.s., Zlín

Thiazolidindiones, glitazones have a significant effect on the metabolism of carbohydrates as well as cardiovascular risk factors. In addition, they exert a beneficial effect on the development of atherosclerotic changes in patients with diabetes and may have a protective effect on the function of pancreatic cells. Glitazone indication are being further specified, and particular attention is being paid to any adverse effects and compromised liver function, weight increase, risk of bone fractures and fluid retention. The author pays special attention to possibly higher risk of myocardial infarction with the use of rosiglitazone and points out the possibility of cardiac failure with the use of glitazone therapy. For the time being, however, there is no reason to change the position of TZDs within the algorhythm of oral drug therapy in the treatment of type 2 diabetes.

Keywords: thiazolidindiones, glitazones, indication, adverse effect, fluid retention, heart failure, bone fractures, weight increase, risk of IM, therapy algorythm

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rybka J. The role of thiazolidindiones in the treatment of type 2 diabetes. Interní Med. 2008;10(2):50-53.
Download citation

References

  1. Bloomgarden ZT. Exploring Treatment Strategies for Type 2 Diabetes. Diabetes Care, 2007; 30(10): 2737-2745. Go to original source... Go to PubMed...
  2. Bloomgarden ZT. The Avandia Debate. Diabetes Care, 2007; 30(9): 2401-2408. Go to original source... Go to PubMed...
  3. Doležal T. Léčba hyperglykemie u pacientů s diabetem 2. typu: konsensus EASD. Farmakoterapie 2007; 3(1): 83-86.
  4. Dormandy JA, Charbonell B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study: a randomized controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
  5. Elte JWF, Bliklé JF. Thiazolidindiones for the treatment of type 2 diabetes. European Journal of Internal Medicine 2007; 18: 18-25. Go to original source... Go to PubMed...
  6. Home PD, Pocock SJ, Beck-Nielsen H, for the RECORD Study outcomes-an interim analysis. N Engl J Med, 2007; 357: 28-38. Go to original source... Go to PubMed...
  7. Kvapil M, Doležalová L. Léčba inzulinem ve vyšším věku. Interní Med. 2007; 9 (10): 434-443.
  8. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidindiones: a meta-analysis of randomized clinical trials. Lancet, 2007; 370: 1129-1136. Go to original source... Go to PubMed...
  9. Leiter LA. ?-cell preservation: a potential role for thiazolidindiones to improve clinical care in type 2 diabetes. Diabet Med 2005; 22: 963-972. Go to original source... Go to PubMed...
  10. Lincoff AM, Wolski K, Nicholls SDJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trial. JAMA 2007; 298: 1180-1188. Go to original source... Go to PubMed...
  11. Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidindiones and cardiovascular outcomes in older patients with diabetes. JAMA, 2007; 298: 2634-2643. Go to original source... Go to PubMed...
  12. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidindiones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation, 2005; 111: 583-590. Go to original source... Go to PubMed...
  13. Misbin RI. Lessons From the Avandia Controversy. Diabetes Care, 2007; 30(12): 3141-3144. Go to original source... Go to PubMed...
  14. Miyazaki Y, et al. J Clin Endocrinol Metab, 2002; 87: 2784-2791. Go to original source... Go to PubMed...
  15. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia, 2008; 51: 8-11. Go to original source... Go to PubMed...
  16. National Heart, Lung, and Blood Institute: Questions and answers: use of rosiglitazone (Avandia) in the National Heart, Lung, and Blood Institute´s Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trials (article online), 2007. Available from http://www.nhlbi.nih.gov/new/press/07-rosi-qa.htm. Accessed 11 July 2007.
  17. Nesto RW. Et al. Circulation, 2003; 108: 2941-2948. Go to original source... Go to PubMed...
  18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007; 356: 2457-2471. Go to original source... Go to PubMed...
  19. Olšovský J. Postavení thiazolidindionů v léčbě diabetes mellitus 2007. Předneseno na slavnostním Diabetologickém dni, ,Pokroky v diabetologii", Zlín 21. 11. 2007.
  20. Pelikánová T. Inzulín v léčbě diabetu 2. typu. Postgraduální medicína - mimořádná příloha 11. 9. 2007, 13-22.
  21. Perušičová J. Co je nového na cestě od diabezity po kardiadiabetes. Praha: Geum 2006: 185 s.
  22. Piťhová P. Thiazolidindiony v roce 2007. Medical Tribune 31/2007: 4-8.
  23. Piťhová P, Perušičová J, Pelikánová M, Žákovičová E, Hollay E. Nehypoglykemizující účinky perorálních antidiabetik. Interní Med. 2007; 9 (11): 507-513.
  24. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med, 2007; 356: 2522-2524. Go to original source... Go to PubMed...
  25. Rosenstock J, et al. Diabetes. 2004; 53 (suppl 2): A 144.
  26. Rybka J. Terapie diabetu 2. typu. In. Diabetes mellitus - komplikace a přidružená onemocnění. Diagnostické a léčebné postupy. Praha: Grada Publ. 2007: 53-66.
  27. Schwartz AV, Sellmeyer DE, Vittighoff E, et al. Thiazolidindione use and bone loss in older diabetic adults. J Clin Endocrinol Metab, 2006; 91: 3349-3354. Go to original source... Go to PubMed...
  28. Svačina Š. Trendy soudobé diabetologie, sv. 10, Praha: Galén 2005, 1. vydání, 225 s.
  29. Škrha J. Současnost a perspektivy léčby diabetu - patofyziologické poznámky. Předneseno na slavnostním Diabetologickém dni, ,Pokroky v diabetologii", Zlín 21. 11. 2007.
  30. Šmahelová A. Inzulinoterapie u pacientů s diabetem 2. typu. Farmakoterapie 2007; 3(1): 34-38.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.